CHNQD-03301
CHNQD-03301 is an orally active hypoxia-inducible factor-1α (HIF-1α) inhibitor (IC50 = 10.97 nM). CHNQD-03301 promotes the proteasomal degradation of HIF-1α protein, leading to its significant suppression. CHNQD-03301 can reverse HIF accumulation-induced angiogenesis and mitigate the HIF-induced erythrocytosis phenotype in zebrafish models. CHNQD-03301 can be used for the study of colon cancer.
For research use only. We do not sell to patients.
- CAS No.: 3104302-65-7
- Formula: C23H20O6
- Molecular Weight:392.40
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
HIF-1α 10.97 nM (IC50) |
In Vitro
CHNQD-03301 (Compound 20) (0.01-1.0 μM, 24 h) dose-dependently reduces HIF-1α protein levels and decreases the expression of downstream target proteins CA9, REDD1, and PDK1 in HCT116 cells, the mRNA expression levels of downstream genes such as CA9, VEGF, and REDD1 are also significantly reduced[1].
CHNQD-03301 (0.4-1.6 μM) significantly reduces EPO mRNA level, inhibiting the hypoxia-induced angiogenesis in HCT116 cells[1].
CHNQD03301 shows the IC50 values for HCT116 cells are 2.31 μM under normoxia and 0.83 μM under hypoxia[1].
CHNQD-03301 (0.4-1.6 μM) induces cell cycle arrest at the G2 phase under hypoxic conditions in HCT116 cells[1].
CHNQD-03301 (0.4-1.6 μM) has no significant effect on HCT116 cell proliferation but markedly inhibits the proliferation of von Hippel-Lindau (VHL)-deficient RCC4 cells[1].
CHNQD-03301 (1-4 μM, 7-14 days) dose-dependently inhibits spheroid formation in HCT116 cells[1].
CHNQD-03301 (0.4-2.0 μM, 24 h) significantly inhibits the migration ability of HCT116 cells under hypoxic conditions and VHL-deficient RCC4 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HCT116 cells, RCC4 cells
-
Concentration:0.01 μM, 0.1 μM, 1.0 μM
-
Incubation Time:24 h
-
Result:Dose-dependently reduced HIF-1α protein levels and decreased the expression of downstream target proteins (CA9, REDD1, PDK1) in HCT116 cells.
Reduced HIF-1α protein levels in HCT116 cells exogenously overexpressing HIF-1α.
Effectively reduced HIF-1α and CA9 protein levels in RCC4 cells (VHL-deficient).
-
Cell Line:HCT116 cells (under hypoxic conditions), VHL-deficient RCC4 cells
-
Concentration:0.4 μM, 0.8 μM, 1.6 μM
-
Incubation Time:24 h
-
Result:Significantly inhibited the migration ability of HCT116 cells under hypoxic conditions and VHL-deficient RCC4 cells.
Parmacokinetics
| Species | Dose | Route | AUC0-t | AUC0-∞ | Tmax | Cmax | T1/2 | MRT0-t | CL | MRT0-∞ | F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Rat | 20 mg/kg | i.p. | 38027.7 ng·h/mL | 42652.2 ng·h/mL | 4.0 h | 3380.9 ng/mL | 9.6 h | 13.2 h | 468.9 mL/h/kg | / | / |
| Rat | 20 mg/kg | p.o. | 35926.6 ng·h/mL | 40869.9 ng·h/mL | 4 h | 2332.2 ng/mL | 9.3 h | / | 489.3 mL/h/kg | 14.1 h | 94.5 % |
In Vivo
CHNQD-03301 (100 mg/kg, p.o., once) shows no acute toxicity at the 100 mg/kg dose in mice, and the maximum tolerated dose (MTD) was above 100 mg/kg, indicating a good safety profile[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:A tumor model was established in female C57BL/6J (8-week-old) mice by subcutaneous injection of MB49 mouse bladder cancer cells (1×105 cells/mouse)[1].
-
Dosage:1 mg/kg
-
Administration:P.o., once daily for 13 days
-
Result:Low-dose oral administration effectively inhibited MB49 tumor growth (TGI = 52.0%) and showed no significant change in mouse body weight.
-
Animal Model:A tumor model was also established in female C57BL/6J (8-week-old) mice by subcutaneous injection of HCT116 human colon cancer cells (2×106 cells/mouse)[1].
-
Dosage:1 mg/kg
-
Administration:P.o., once daily for 19 days
-
Result:Low-dose oral administration effectively inhibited MB49 tumor growth (TGI = 51.0%) and showed no significant change in mouse body weight.
-
Animal Model:Healthy female ICR mice[1].
-
Dosage:100 mg/kg
-
Administration:P.o., once
-
Result:None of the mice died within 7 days.
No apparent difference in blood biochemistry parameters, including ALT, AST, LDH, UREA, CREA, UA, and CK.
Hematoxylin and eosin (H&E) staining results presented no pathological changes in the collected tissues (hearts, livers, spleens, lungs, kidneys, and duodenum).
Chemical Information
-
CAS No. 3104302-65-7
-
Molecular Weight 392.40
-
Formula C23H20O6
-
SMILES
OC1=CC=C(C2=CC(OC)=C3C(OC4=CC(OC(C)(C)O5)=C5C=C34)=C2OC)C=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Human pluripotent stem cell endothelial-cell differentiation
Human pluripotent stem cell endothelial differentiation is based on stepwise developmental patterning: early activation of WNT/GSK3β inhibition promotes mesodermal or vascular progenitor entry, followed by endothelial specification using VEGF-related signaling, BMP4, FGF2, Notch modulation, or cAMP depending on the published protocol. Endothelial differentiation is read out by acquisition of CD31, CD34, VE-cadherin/CD144, KDR/VEGFR2, vWF, Tie2, NOS3, acetylated LDL uptake, tube/network formation, barrier function, and in vivo vessel-forming capacity where tested.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Vascular/Branching Fractal Analysis
Vascular/branching fractal analysis quantifies the geometric complexity of vessel trees or vascular networks from segmented 2D images, commonly by converting vessels into binary and/or skeletonized maps and estimating fractal dimension using box-counting or related approaches. Fractal dimension is interpreted as an image-derived readout of vascular branching complexity, space filling, or density, and has been applied to retinal photographs, fluorescein angiography, OCT angiography, capillary perfusion maps, and in vitro Matrigel angiogenesis networks. The assay readout is generated from vessel-positive pixels after image preprocessing, vessel segmentation, binarization, and optional skeletonization; reported outputs include fractal dimension, vessel density, branchpoint density, endpoint density, vessel length density, tortuosity, and generation-based branching metrics when VESGEN-style analysis is used. The biological interpretation is limited to quantitative vascular patterning and s
-
Endothelial Tube Formation Assay
Endothelial tube formation assay evaluates the ability of endothelial cells to attach, migrate, align, and organize into capillary-like networks when cultured on gelled basement membrane extract or Matrigel; the readout is the morphology and quantity of tube-like networks, which reflects an in vitro endothelial morphogenesis step related to angiogenesis. Basement membrane extract/Matrigel provides laminin-rich extracellular matrix cues that support endothelial differentiation into capillary-like structures, but it can contain biologically active growth factors, so growth-factor-reduced matrix is preferred when testing defined angiogenic stimulators or inhibitors.
-
Endothelial Cell Migration/Angiogenic Sprouting Assay
Endothelial cell migration and angiogenic sprouting assays are in vitro (and partially ex vivo-adapted) functional models that quantify the ability of endothelial cells to undergo coordinated migration, extracellular matrix invasion, and multicellular organization into capillary-like sprouts in response to pro-angiogenic stimuli such as VEGF, bFGF, or conditioned microenvironments. These assays are used to model early angiogenic events including tip-cell formation, directional migration, and lumen-like sprout extension, which collectively reflect angiogenic activation and vascular morphogenesis processes observed in vivo.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)